The study investigates the anti-inflammatory effects of insulin on Toll Like Receptors (TLRs), which are implicated in atherosclerosis and cardiovascular diseases. Given the rising prevalence of obesity and type 2 diabetes, this research could provide insights into novel therapeutic approaches for managing inflammation-related complications in these populations. The findings may enhance the value proposition of insulin therapies, particularly in the context of cardiovascular health, potentially leading to expanded indications and market opportunities. The collaboration with the American Diabetes Association may also enhance credibility and visibility within the diabetes care community. However, the competitive landscape includes existing anti-inflammatory agents and novel therapies targeting similar pathways, necessitating a thorough competitive analysis.